Biopharmas Unveil Early Cancer-Drug Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts mine April’s AACR meeting for tomorrow’s blockbusters.
You may also be interested in...
Despite Exubera Scare, Mannkind Marches On
Fair or not, “cancer” word repels patients and doctors, analyst tells “The Pink Sheet” DAILY.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.